Sionna Therapeutics (NASDAQ:SION) Director Sells $2,165,637.06 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $44.61, for a total value of $2,165,637.06. Following the completion of the transaction, the director owned 2,916,228 shares in the company, valued at $130,092,931.08. This represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58.
• On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.58, for a total value of $2,664,412.86.
• On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.52, for a total value of $131,244.96.
• On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.68, for a total value of $2,341,097.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.51, for a total value of $2,128,201.14.

Sionna Therapeutics Price Performance

Shares of SION stock opened at $43.12 on Thursday. Sionna Therapeutics, Inc. has a 1-year low of $11.77 and a 1-year high of $48.44. The stock’s fifty day moving average price is $39.11 and its 200 day moving average price is $39.51. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -22.34 and a beta of 1.35.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, equities research analysts anticipate that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Key Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Sionna Therapeutics and kept a $58 price target, implying meaningful upside from recent trading levels and reinforcing optimism around the company’s clinical pipeline. Article Title
• Positive Sentiment: Sionna Therapeutics said management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 20, which can give investors a fresh update on the company’s cystic fibrosis programs and keep attention on the story. Article Title
• Neutral Sentiment: In its first-quarter update, the company said enrollment is complete in the PreciSION CF Phase 2a trial for SION-719 and that topline data is expected in summer 2026, while the SION-451 Phase 1 study is also on track. It also reported a strong cash balance of about $289.9 million, supporting operations into 2028. Article Title
• Negative Sentiment: Sionna reported a first-quarter loss of $0.60 per share, wider than the expected $0.52 loss, which may weigh on sentiment even though the company remains pre-revenue and focused on clinical development. Article Title
• Negative Sentiment: Director OrbiMed Advisors and director Peter A. Thompson disclosed several large share sales in recent days. The transactions were made under pre-arranged 10b5-1 plans, but the size of the selling can still pressure investor sentiment. Article Title

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SION. BTIG Research restated a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a research note on Wednesday. Wedbush began coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They set an “outperform” rating and a $53.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Finally, Guggenheim boosted their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.00.

Institutional Trading of Sionna Therapeutics

Large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in Sionna Therapeutics during the 4th quarter valued at about $36,000. Russell Investments Group Ltd. purchased a new stake in Sionna Therapeutics during the 3rd quarter valued at about $30,000. Balyasny Asset Management L.P. purchased a new stake in Sionna Therapeutics during the 4th quarter valued at about $58,000. BNP Paribas Financial Markets purchased a new stake in Sionna Therapeutics during the 2nd quarter valued at about $31,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Sionna Therapeutics during the 4th quarter valued at about $89,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.